908 Devices Inc. (NASDAQ:MASS) CEO Kevin J. Knopp Acquires 10,000 Shares

908 Devices Inc. (NASDAQ:MASS - Get Free Report) CEO Kevin J. Knopp purchased 10,000 shares of the company's stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average cost of $6.42 per share, with a total value of $64,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 508,981 shares in the company, valued at $3,267,658.02. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

908 Devices Price Performance

Shares of NASDAQ MASS traded up $0.86 during midday trading on Monday, hitting $6.56. The stock had a trading volume of 1,634,899 shares, compared to its average volume of 200,745. The company's 50-day simple moving average is $6.34 and its 200 day simple moving average is $7.09. The firm has a market cap of $226.25 million, a P/E ratio of -6.13 and a beta of 1.02. 908 Devices Inc. has a fifty-two week low of $4.85 and a fifty-two week high of $12.51.

908 Devices (NASDAQ:MASS - Get Free Report) last released its earnings results on Tuesday, April 30th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.03. The company had revenue of $9.99 million during the quarter, compared to analysts' expectations of $9.29 million. 908 Devices had a negative return on equity of 20.87% and a negative net margin of 68.57%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm earned ($0.39) EPS. Equities analysts expect that 908 Devices Inc. will post -1.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System bought a new position in shares of 908 Devices in the 1st quarter worth $80,000. Values First Advisors Inc. boosted its position in shares of 908 Devices by 24.5% in the 3rd quarter. Values First Advisors Inc. now owns 16,726 shares of the company's stock worth $111,000 after purchasing an additional 3,294 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of 908 Devices in the 4th quarter worth $133,000. Arete Wealth Advisors LLC boosted its position in shares of 908 Devices by 35.8% in the 3rd quarter. Arete Wealth Advisors LLC now owns 22,758 shares of the company's stock worth $152,000 after purchasing an additional 5,997 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of 908 Devices by 15.3% in the 3rd quarter. New York State Common Retirement Fund now owns 70,525 shares of the company's stock worth $470,000 after purchasing an additional 9,346 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Stephens reissued an "overweight" rating and issued a $14.00 target price on shares of 908 Devices in a research note on Monday.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.